NASDAQ · STTK
Shattuck Labs, Inc.
$5.72-$0.09 (-1.46%)
Shattuck Labs, Inc.’s quoted price sits in the upper half of its reported 52-week range, 31.33% below the high.
Loading market information…
NASDAQ · ATRA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Atara Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.46% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Atara Biotherapeutics, Inc.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -$0.13. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Atara Biotherapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral infections. A key therapeutic candidate, tabelecleucel, is currently undergoing Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease, as well as various hematologic and solid tumors, such as nasopharyngeal carcinoma. The company is also advancing a robust pipeline of next-generation CAR T immunotherapies designed to combat hematologic malignancies and solid tumors. This includes ATA2271 and ATA3271 targeting mesothelin, alongside ATA2431 and ATA3219 for B-cell malignancies. Furthermore, Atara is developing ATA188 for the treatment of multiple sclerosis and the ATA368 program specifically for cancers associated with human papillomavirus (HPV). To bolster its research and development efforts, Atara Biotherapeutics has established significant collaborations and licensing agreements. These include a licensing partnership with Memorial Sloan Kettering Cancer Center, a license and R&D collaboration with QIMR Berghofer Medical Research Institute, and a strategic alliance with H. Lee Moffitt Cancer Center. Additionally, the company holds a strategic partnership with Bayer AG focused on mesothelin-targeted CAR T-cell therapies for solid tumors.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:08 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 15, 2025 | $3.50+214.01% vs estimate | $98.15M+2,182.53% vs estimate |
|---|
| Q4 2024 | Mar 7, 2025 | -$1.19+68.85% vs estimate | $32.75M+59.12% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | -$2.93+22.28% vs estimate | $40.19M+21.44% vs estimate |
|---|
THE ANALYST VIEW
13 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $13.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$5.72-$0.09 (-1.46%)
Shattuck Labs, Inc.’s quoted price sits in the upper half of its reported 52-week range, 31.33% below the high.
$2.56+$0.11 (+4.49%)
Ovid Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 17.68% below the high.
$1.72-$0.02 (-0.87%)
InflaRx N.V.’s quoted price sits in the lower half of its reported 52-week range, 41.86% below the high.
$4.23+$0.07 (+1.68%)
Oramed Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.67% below the high.
$2.38-$0.09 (-3.64%)
MacroGenics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.15% below the high.
$9.14-$0.15 (-1.61%)
Sutro Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.16% below the high.
$3.98-$0.08 (-1.97%)
Coya Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.88% below the high.
$4.81-$0.11 (-2.24%)
Champions Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.12% below the high.
